ClinicalTrials.gg
RecruitingNCT07117214Updated Aug 27, 2026

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

A Phase 1 interventional study of [68Ga]Ga-DWJ155 in Breast Neoplasms and Carcinoma, Non-Small-Cell Lung, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 199 studies in Breast Neoplasms by Novartis — 16 open to participants now, 30 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
122nd of 155
36 · median 104
Started
2026
with 9 others
Phase 1
40 of 199
6 open now
Primary completion
2029-01
later than 16 of 29 live
Registered
182nd of 199
by date

Among the 199 studies in Breast Neoplasms by Novartis, this one is the 122nd largest by planned enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 16 of the 29 other live ones, and was the 182nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 199 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.

Read the detailed description

This is a first-in-human (FIH), open-label, phase I radioligand imaging study designed to assess the biodistribution, imaging, safety, PK and dosimetry properties in patients with aBC and aNSCLC adenocarcinoma.

Approximately 15-21 aBC and 9-15 aNSCLC patients will be enrolled into the study. All patients enrolled in the study will receive a single administered radioactive dose of FKL480. The study will consist of an imaging characterization part and an expansion part.

03

Conditions studied

  • Breast Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Breast cancer
  • Non-small cell lung cancer
  • Radioligand imaging
  • [68Ga]Ga-DWJ155
  • FKL480
  • gallium
  • adenocarcinoma
  • ductal
  • lobular
  • positron emission tomography (PET)
  • dosimetry
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Patients with or cytologically confirmed and documented HR+/- advanced breast cancer (aBC), advanced defined as locoregionally advanced unresectable or , either untreated or currently receiving of systemic therapy OR patients with histologically or cytologically confirmed and documented HER2+ aBC, advanced defined as locoregionally advanced unresectable or metastatic, either untreated or (r/r) after one or more lines of treatment OR patients with histologically or cytologically confirmed and documented advanced NSCLC (aNSCLC) adenocarcinoma, advanced defined as locoregionally unresectable or metastatic, either untreated or currently receiving first line of systemic therapy.
  • Presence of (at least one target lesion) according to v1.1 assessed by conventional CT scan.

Exclusion criteria

Exclusion Criteria:

  • Patients having out of range laboratory values for kidney function and blood markers as defined in the study protocol
  • Patients with inadequate hepatic function
  • Unmanageable urinary tract obstruction or urinary incontinence

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Advanced breast cancer

    Patients will receive FKL480 (\[68Ga\]Ga-DWJ155)

    Drug: [68Ga]Ga-DWJ155

  • Experimental
    Advanced NSCLC

    Patients will receive FKL480 (\[68Ga\]Ga-DWJ155)

    Drug: [68Ga]Ga-DWJ155

Interventions

06

What researchers measure

Primary outcomes

  1. Standard Uptake Value (SUV) mean and max of FKL480 uptake in normal organs and tumor lesions over time

    Imaging properties of FKL480 will be evaluated by assessing radiotracer uptake, identified via positron emission tomography (PET) scans. The SUVmean and SUVmax will be calculated and reported with summary statistics.

    Time frame: Up to 240 minutes after dosing on Day 1

  2. Standard Uptake Value ratio (SUVr) of FKL480 uptake in normal organs and tumor lesions over time

    SUVr will be calculated by dividing the SUV of the lesions by the SUV of the different organs in order to identify the reference organ with the lowest uptake and the respective SUVr (i.e. using SUVmean or SUVmax).

    Time frame: Up to 240 minutes after dosing on Day 1

Secondary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Incidence and severity of AEs and SAEs, including changes in vital signs and laboratory values qualifying and reported as AEs.

    Time frame: Up to 3 days after single dose administration on Day 1

  2. Dosimetry sub-group: Observed maximum concentration (Cmax) of FKL480 based on blood radioactivity data

    The FKL480 pharmacokinetic analysis will be performed based on blood radioactivity concentration data, obtained by measuring in gamma-counting equipment the blood samples.

    Time frame: Up to 240 minutes after dosing on Day 1

  3. Dosimetry sub-group: Observed area under the curve (AUC) from time zero to the last measurable concentration sampling time (AUClast) of FKL480 based on blood radioactivity data

    The FKL480 pharmacokinetic analysis will be performed based on blood radioactivity concentration data, obtained by measuring in gamma-counting equipment the blood samples

    Time frame: Up to 240 minutes after dosing on Day 1

  4. Dosimetry sub-group: Observed time to reach maximum (Tmax) after single dose administration of FKL480 based on blood radioactivity data

    The FKL480 pharmacokinetic analysis will be performed based on blood radioactivity concentration data, obtained by measuring in gamma-counting equipment the blood samples

    Time frame: Up to 240 minutes after dosing on Day 1

  5. Dosimetry sub-group: Urinary excretion of FKL480

    The elimination of the compound in urine will be evaluated based on urine radioactivity concentration data obtained by measuring in gamma counting equipment the urine samples.

    Time frame: Up to 240 minutes after dosing on Day 1

  6. Dosimetry sub-group: Absorbed radiation dose in normal tissues and total body

    Absorbed radiation dose coefficients in selected organs and lesions and total body as measured by image quantification.

    Time frame: Up to 240 minutes after dosing on Day 1

  7. Dosimetry sub-group: Effective dose

    Effective dose in selected organs and total body as measured by image quantification.

    Time frame: Up to 240 minutes after dosing on Day 1

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Groningen, Provincie Groningen 9728 NZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 31 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 12, 2025
StartActual
Jun 26, 2026
Primary completionEst.
Jan 26, 2029
CompletionEst.
Jan 26, 2029
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07117214
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Jun 26, 2026
Primary completion
Jan 26, 2029 (estimated)
Completion
Jan 26, 2029 (estimated)
Last update
Aug 27, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion